argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117

argenx (Nasdaq:ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the addition of a new pipeline candidate, ARGX-117, targeting the complement cascade with therapeutic potential in autoantibody-mediated indications.

As quoted in the press release:

“We obtained the rights to ARGX-117 as part of our Innovative Access Program through which we identified the groundbreaking work on this antibody with Broteio Pharma. The mechanism of action of ARGX-117 may allow us to explore its potential benefit across a range of complement-mediated indications. In addition, ARGX-117 may synergize with our lead autoimmune compound ARGX-113, targeting FcRn in order to clear pathogenic immunoglobulin G (IgG) antibodies, while our new complement-targeted antibody can also address immunoglobulin M (IgM)-mediated autoimmune diseases,” commented Tim Van Hauwermeiren, CEO of argenx.

Click here to read the full press release.